Seer (SEER) AI Stock Analysis

• Market Cap: $125.98M
• Dividend Yield: N/A
• Average Volume (3M): 113.15K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.28
• Revenue Growth: 13.77%
• EPS Growth: -4.76%
• Country: US
• Employees: 134
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.29
• Shares Outstanding: 56,251,522
• 10 Day Avg. Volume: 70,395
• 30 Day Avg. Volume: 113,152
• PEG Ratio: -0.56
• Price to Book (P/B): 0.44
• Price to Sales (P/S): 10.33
• P/FCF Ratio: -2.90
• Enterprise Value/Market Cap: 0.77
• Enterprise Value/Revenue: 5.93
• Enterprise Value/Gross Profit: 14.57
• Enterprise Value/Ebitda: -1.36
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -1.36
• Revenue Forecast (FY): $22.10M

• Rating: 54 Neutral
• Price Target: $2.00 ▼(-3.85% Downside)
• Action: Reiterated Date: 11/07/25
• Date: Action: Reiterated 11/07/25

Seer's overall stock score is primarily influenced by its financial performance, which shows strong revenue growth but significant profitability challenges. Technical analysis suggests a potential upward trend, but valuation concerns due to ongoing losses weigh heavily. The earnings call provided mixed signals, with strong demand offset by minimal growth and external challenges.

Positive Factors

Validated Proteograph demand

Strong, repeated instrument shipments and recorded customer uptake demonstrate product-market fit for the Proteograph platform. Durable demand and adoption reduce commercialization risk, supporting recurring instrument and reagent revenue streams and enabling scale benefits across multi-year large cohort studies.

Robust top-line growth (TTM)

Sustained high revenue growth indicates expanding commercial traction and addressable market penetration. If growth persists, it can support operating leverage, investment in R&D and ecosystem partnerships, and provide a base to improve margins as fixed costs spread over larger revenue.

Strong liquidity and capital actions

A substantial cash position and active share repurchase program signal strong liquidity and financial flexibility to fund R&D, operations, and strategic initiatives. Cash reserves reduce short-term financing risk and can finance commercialization of Proteograph or strategic partnerships without dilutive capital raises.

Negative Factors

Severe negative profitability

Extremely wide negative margins reflect structural operating losses and high fixed or variable costs relative to revenue. Persistent deep unprofitability can deplete cash reserves over time, restrict reinvestment capacity, and require sustainable margin improvement before equity returns can be realized.

Negative return on equity

A materially negative ROE indicates the company is destroying shareholder capital rather than creating it. Without sustained profit recovery or meaningful margin expansion, negative returns constrain long-term investor value creation and raise questions about operational efficiency and capital allocation.

Weakened cash generation trends

Declining free cash flow and negative operating cash conversion suggest operations are not yet self-sustaining. Continued weak cash generation increases reliance on existing cash reserves and may limit spending on commercialization, slowing the path to break-even and heightening financing risk if losses persist.

Seer Business Overview & Revenue Model

Company Description

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

How the Company Makes Money

Seer generates revenue primarily through the sale of its proteomic analysis platforms and related consumables to research institutions and pharmaceutical companies. Additionally, the company may earn revenue through service contracts where it conducts custom proteomic analyses for clients. Key partnerships with academic institutions and collaborations with pharmaceutical companies enhance its market presence and provide opportunities for joint research projects, which can also contribute to its earnings. Furthermore, grants and funding from governmental and private entities aimed at advancing proteomic research can serve as additional revenue sources.

Seer Financial Statement Overview

Summary

Seer shows strong revenue growth but faces significant profitability and cash flow challenges. The low leverage is positive, but negative returns on equity and cash flow issues highlight the need for operational improvements.

Income Statement

Seer's income statement shows a significant revenue growth of 54.8% in the TTM period, indicating strong top-line expansion. However, the company is facing substantial profitability challenges with a negative net profit margin of -510.57% and negative EBIT and EBITDA margins. These figures highlight ongoing operational inefficiencies and high expenses relative to revenue.

Balance Sheet

The balance sheet reflects a conservative financial structure with a low debt-to-equity ratio of 0.086, suggesting limited leverage and financial risk. However, the return on equity is negative at -25.93%, indicating that the company is not generating positive returns on shareholders' equity, which is a concern for investors.

Cash Flow

Seer's cash flow statement shows a decline in free cash flow growth by -15.53% in the TTM period, which is concerning. The operating cash flow to net income ratio is negative, reflecting cash flow challenges. However, the free cash flow to net income ratio is slightly positive at 1.06, suggesting some ability to cover net losses with free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	16.33M	13.95M	15.18M	14.69M	6.39M	656.00K
Gross Profit	6.65M	6.83M	1.45M	384.00K	-374.00K	-950.00K
EBITDA	-71.41M	-93.92M	-80.70M	-87.06M	-67.61M	-31.17M
Net Income	-79.35M	-86.60M	-86.28M	-92.97M	-71.17M	-32.77M
Balance Sheet
Total Assets	308.61M	366.60M	436.27M	487.93M	539.14M	442.32M
Cash, Cash Equivalents and Short-Term Investments	199.24M	236.41M	316.22M	421.24M	400.07M	431.86M
Total Debt	24.25M	25.96M	28.26M	29.87M	23.32M	0.00
Total Liabilities	36.79M	39.03M	39.37M	40.94M	36.22M	10.71M
Stockholders Equity	271.81M	327.57M	396.90M	446.99M	502.92M	431.61M
Cash Flow
Free Cash Flow	-46.07M	-49.69M	-66.37M	-71.05M	-53.27M	-25.36M
Operating Cash Flow	-45.10M	-46.11M	-59.06M	-60.78M	-46.35M	-20.83M
Investing Cash Flow	64.42M	65.86M	37.90M	-122.72M	-170.88M	-34.56M
Financing Cash Flow	-11.97M	-11.49M	452.00K	3.89M	116.63M	371.49M

Seer Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.08
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SEER, the sentiment is Positive. The current price of 2.08 is above the 20-day moving average (MA) of 1.93, above the 50-day MA of 1.89, and above the 200-day MA of 2.05, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 62.47 is Neutral, neither overbought nor oversold. The STOCH value of 66.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SEER.

Seer Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IKT	54 Neutral	$248.60M	-3.75	-131.71%	―	-100.00%	79.01%
SEER	54 Neutral	$125.98M	-1.53	-25.74%	―	13.77%	-4.76%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SRZN	50 Neutral	$231.43M	-1.24	―	―	-63.96%	-28.50%
TCRX	49 Neutral	$59.59M	-0.99	-76.44%	―	-10.03%	11.06%
CGTX	47 Neutral	$91.81M	-2.36	-109.73%	―	―	50.39%
TIL	44 Neutral	$60.77M	-0.75	-50.60%	―	―	1.40%

Seer Corporate Events

Seer Retires Class B Common Stock Shares

On December 12, 2025, Seer Company filed a Certificate of Retirement with the Delaware Secretary of State to retire its Class B Common Stock shares that were issued but not outstanding. This action reduces the company’s authorized shares of capital stock and Class B Common Stock. The Class A Common Stock will continue trading on Nasdaq under the symbol ‘SEER’ with the same CUSIP number.

The most recent analyst rating on (SEER) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Seer stock, see the SEER Stock Forecast page.